

# Enrique Trilla

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2108019/enrique-trilla-publications-by-year.pdf>  
**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66 papers	1,116 citations	15 h-index	32 g-index
96 ext. papers	1,324 ext. citations	2.8 avg, IF	3.58 L-index

#	Paper	IF	Citations
66	Re: Magdalena Götze, Jan Philipp Radtke, Gencay Hatiboglu, et al. The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies. <i>Eur Urol Focus</i> 2021;7:325-31.. <i>European Urology Focus</i> , <b>2022</b> ,	5.1	1
65	Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category.. <i>European Urology Open Science</i> , <b>2022</b> , 37, 38-44	0.9	1
64	Perioperative and Functional Outcomes of Robot-assisted Ureteroenteric Reimplantation: A Multicenter Study of Seven Referral Institutions.. <i>European Urology Open Science</i> , <b>2022</b> , 35, 47-53	0.9	0
63	Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?. <i>International Journal of Biological Markers</i> , <b>2022</b> , 3936155221081537	2.8	1
62	The Barcelona Predictive Model of Clinically Significant Prostate Cancer.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
61	Definition of Castrate Resistant Prostate Cancer: New Insights.. <i>Biomedicines</i> , <b>2022</b> , 10,	4.8	3
60	Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review.. <i>BMC Cancer</i> , <b>2022</b> , 22, 357	4.8	
59	Proclarix, A New Biomarker for the Diagnosis of Clinically Significant Prostate Cancer: A Systematic Review.. <i>Molecular Diagnosis and Therapy</i> , <b>2022</b> , 26, 273	4.5	1
58	Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy. <i>Cancers</i> , <b>2022</b> , 14, 2374	6.6	
57	Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI. <i>Cancers</i> , <b>2022</b> , 14, 2702	6.6	
56	The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer.. <i>World Journal of Men's Health</i> , <b>2021</b> ,	6.8	2
55	Prediction of clinically significant prostate cancer after negative prostate biopsy: The current value of microscopic findings. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 432.e11-432.e19	2.8	
54	Nuclear and cytosolic pS727-STAT3 levels correlate with overall survival of patients affected by clear cell renal cell carcinoma (ccRCC). <i>Scientific Reports</i> , <b>2021</b> , 11, 6957	4.9	0
53	The position of urethrovesical anastomosis after robotic radical prostatectomy assessed by MRI predicts early functional recovery: A cohort analyses from a randomized clinical trial. <i>European Journal of Radiology</i> , <b>2021</b> , 137, 109589	4.7	1
52	A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical Prostatectomy. <i>European Urology Oncology</i> , <b>2021</b> ,	6.7	4
51	Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions. <i>European Urology</i> , <b>2021</b> , 81, 124-124	10.2	1
50	Prostatic-specific antigen density behavior according to multiparametric magnetic resonance imaging result. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 410-417	2.8	7

49	Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e11889	12	3
48	Serum Luteinizing Hormone Testing Can Identify Optimal Medical Castration. <i>European Urology Open Science</i> , <b>2020</b> , 19, 24-26	0.9	1
47	Analysis of the nuclear expression of pSer727-STAT3 as a prognostic factor in patients with clear cell renal carcinoma. <i>Actas Urológicas Españolas</i> , <b>2020</b> , 44, 245-250	0.7	
46	A Robot-Assisted Complete Urinary Tract Extirpation in a Patient with Simultaneous Panurothelial Carcinoma: A Case Report. <i>Journal of Endourology Case Reports</i> , <b>2020</b> , 6, 483-486	0.3	
45	Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review. <i>BMC Urology</i> , <b>2020</b> , 20, 99	2.2	3
44	How to implement magnetic resonance imaging before prostate biopsy in clinical practice: nomograms for saving biopsies. <i>World Journal of Urology</i> , <b>2020</b> , 38, 1481-1491	4	5
43	Association among the R.E.N.A.L. nephrometry score and clinical outcomes in patients with small renal masses treated with percutaneous contrast enhanced ultrasound radiofrequency ablation. <i>Central European Journal of Urology</i> , <b>2019</b> , 72, 92-99	0.9	0
42	Early continence after radical prostatectomy: A systematic review. <i>Actas Urológicas Españolas</i> , <b>2019</b> , 43, 526-535	0.7	2
41	Preoperative magnetic resonance imaging in predicting early continence recovery after robotic radical prostatectomy. <i>Actas Urológicas Españolas</i> , <b>2019</b> , 43, 137-142	0.7	5
40	The role of STAT3 protein as a prognostic factor in the clear cell renal carcinoma. Systematic review. <i>Actas Urológicas Españolas</i> , <b>2019</b> , 43, 118-123	0.7	6
39	The role of negative magnetic resonance imaging: can we safely avoid biopsy in P.I.-R.A.D.S. 2 as in P.I.-R.A.D.S. 1?. <i>Scandinavian Journal of Urology</i> , <b>2019</b> , 53, 21-25	1.6	3
38	Under-expression of CK2β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival. <i>Oncotarget</i> , <b>2018</b> , 9, 5736-5751	3.3	7
37	Systematic review of kidney transplantation functional predictors. <i>Actas Urológicas Españolas</i> , <b>2018</b> , 42, 218-226	0.7	2
36	Ultrasound-guided percutaneous radiofrequency ablation for treating small renal masses. <i>Actas Urológicas Españolas</i> , <b>2017</b> , 41, 497-503	0.7	2
35	Systematic review of renal carcinoma prognostic factors. <i>Actas Urológicas Españolas</i> , <b>2017</b> , 41, 215-225	0.7	8
34	Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer. <i>Scandinavian Journal of Urology</i> , <b>2016</b> , 50, 425-428	1.6	7
33	Hormonal changes after localized prostate cancer treatment. Comparison between external beam radiation therapy and radical prostatectomy. <i>Actas Urológicas Españolas</i> , <b>2016</b> , 40, 549-555	0.7	6
32	Utility of the RENAL index -Radius; Exophytic/endophytic; Nearness to sinus; Anterior/posterior; Location relative to polar lines- in the management of renal masses. <i>Actas Urológicas Españolas</i> , <b>2016</b> , 40, 601-607	0.7	5

31	Patient-derived AVATAR mouse models to predict prognosis in advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 551-551	2.2	2
30	Effects of holmium laser enucleation of the prostate on sexual function. <i>Journal of Endourology</i> , <b>2015</b> , 29, 332-9	2.7	26
29	Renal cell carcinoma avatar mouse models for the personalized cancer therapy era.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15627-e15627	2.2	
28	HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome. <i>Cancer Research</i> , <b>2014</b> , 74, 1416-28	10.1	56
27	Extensive emphysematous pyelonephritis in a renal allograft: case report and review of literature. <i>Transplant Infectious Disease</i> , <b>2014</b> , 16, 642-7	2.7	7
26	Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy. <i>Rheumatology International</i> , <b>2014</b> , 34, 1419-25	3.6	3
25	The reproducibility and predictive value on outcome of renal biopsies from expanded criteria donors. <i>Kidney International</i> , <b>2014</b> , 85, 1161-8	9.9	97
24	Native ureteropyelostomy in the treatment of obstructive uropathy in adult renal transplant. Experience and technical alternatives. <i>Actas Urológicas Españolas</i> , <b>2014</b> , 38, 552-6	0.7	1
23	Hepatitis A virus cellular receptor 1/kidney injury molecule-1 is a susceptibility gene for clear cell renal cell carcinoma and hepatitis A virus cellular receptor/kidney injury molecule-1 ectodomain shedding a predictive biomarker of tumour progression. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 2034-47	7.5	21
22	Current status of pediatric donor en bloc kidney transplantation to young adult recipients. <i>Actas Urológicas Españolas</i> , <b>2013</b> , 37, 383-6	0.7	3
21	Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. <i>Urologia Internationalis</i> , <b>2013</b> , 90, 41-4	1.9	22
20	2103 INFLUENCE OF 5 $\alpha$ REDUCTASE INHIBITORS (5-ARI) TREATMENT ON HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP). <i>Journal of Urology</i> , <b>2011</b> , 185,	2.5	1
19	Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome. <i>BJU International</i> , <b>2011</b> , 108, E71-6	5.6	26
18	Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR. <i>BJU International</i> , <b>2010</b> , 105, 202-7	5.6	32
17	Preoperative prediction of pathologically insignificant prostate cancer in radical prostatectomy specimens: the role of prostate volume and the number of positive cores. <i>Urologia Internationalis</i> , <b>2010</b> , 84, 153-8	1.9	14
16	Bilateral testicular germ cell tumours: a single hospital experience. <i>Clinical and Translational Oncology</i> , <b>2010</b> , 12, 299-302	3.6	9
15	Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. <i>BJU International</i> , <b>2009</b> , 104, 1637-40	5.6	31
14	Is there a relationship between prostate volume and Gleason score?. <i>BJU International</i> , <b>2008</b> , 102, 563-5	5.6	8

13	Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. <i>Journal of Urology</i> , <b>2007</b> , 178, 1290-5	2.5	199
12	The relationship between daily calcium intake and bone mineral density in men with prostate cancer. <i>BJU International</i> , <b>2007</b> , 99, 812-5; discussion 815-6	5.6	39
11	Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. <i>Urology</i> , <b>2007</b> , 69, 500-4	1.6	127
10	Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. <i>Urologia Internationalis</i> , <b>2006</b> , 77, 135-8	1.9	55
9	Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. <i>Journal of Urology</i> , <b>2006</b> , 175, 1679-83; discussion 1683	2.5	80
8	Correlation between the biopsies in marginal donor kidneys for transplantation: is it necessary to biopsy both kidneys?. <i>Transplantation Proceedings</i> , <b>2006</b> , 38, 1270-3	1.1	4
7	Case report: retroperitoneal fibrosis simulating local relapse of sarcomatoid renal cell carcinoma. <i>International Urology and Nephrology</i> , <b>2006</b> , 38, 463-5	2.3	5
6	Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer. <i>Anti-Cancer Drugs</i> , <b>2005</b> , 16, 863-6	2.4	7
5	Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer. <i>International Journal of Biological Markers</i> , <b>2005</b> , 20, 209-16	2.8	15
4	Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. <i>International Journal of Cancer</i> , <b>2004</b> , 108, 877-81	7.5	45
3	Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. <i>European Urology</i> , <b>2003</b> , 44, 661-5	10.2	49
2	The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml. <i>European Urology</i> , <b>2002</b> , 42, 333-7	10.2	13
1	Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer. <i>International Journal of Biological Markers</i> , <b>2002</b> , 17, 239-43	2.8	2